Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.

Trial Details

NCT ID
NCT06680752
Phase
PHASE1 / PHASE2
Sponsor
ARCE Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ARD103
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Documented diagnosis of AML with either refractory or relapsed disease or diagnosis of MDS and ≥ 5% BM blasts
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematologic status:
  • Absolute lymphocyte count (ALC) \> 100/mm3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →